Abstract
ABSTRACTThe number of candidate molecules for new non-narcotic analgesics is extremely limited. Here we report the identification of thiowurtzine, a new potent analgesic molecule with promising application in chronic pain treatment. We describe the chemical synthesis of this unique compound derived from the hexaazaisowurtzitane (CL-20) explosive molecule. Then we use animal experiments to assess its analgesic activity in vivo upon chemical, thermal and mechanical exposures, compared to the effect of several reference drugs. Finally, we investigate the potential receptors of thiowurtzine in order to better understand its complex mechanism of action. We use docking, molecular modeling and molecular dynamics simulations to identify and characterize the potential targets of the drug and confirm the results of the animal experiments. Our findings finally indicate that thiowurtzine may have a complex mechanism of action, by targeting the mu, kappa, delta and ORL1 opioid receptors, and the voltage-gated calcium channels as well.
Publisher
Cold Spring Harbor Laboratory
Reference55 articles.
1. Severe Chronic Pain – the Reality of Treatment in Europe;Current Medical Research and Opinion,2011
2. Trends in Medical Use of Opioids in the U.S., 2006–2016
3. Cawich, S. O. , Deonarine, U. , Harding, H. E. , Dan, D. , Na-raynsingh, V. Chapter 46 - Cannabis and Postoperative Analgesia. In Handbook of Cannabis and Related Pathologies; Preedy, V. R. , Ed., Academic Press: San Diego, 2017; pp 450–458. https://doi.org/10.1016/B978-0-12-800756-3.00052-1.
4. Clinical guidelines "Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice";Modern Rheumatology Journal,2015
5. Multimodal Analgesia for Chronic Pain: Rationale and Future Directions;Pain Med,2009